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Introduction
Globally, in 2019, HIV infection was still responsible 
for 1.7 million new infections (range: 1.2 million - 2.2 
million) and for 690,000 (range: 500,000-970,000) 
deaths in the same year [1].
In Italy, in 2018, 2,847 new HIV infections were reported 
and, despite the continuous progress in terms of screening, 
661 new cases of AIDS were notified [2]. The median age 
of new HIV diagnoses is 39 years for males and 38 years 
for females, with a higher incidence between 25 and 39 
years [2]. Antiretroviral therapy (ART) and pre-exposure 
prophylaxis (PrEP) have the potential to massively decrease 
the global burden of HIV new infections; however, no 
“one size fits all” approach can reach the ambitious goal 
of HIV eradication [3]. Moreover, in time of health-care 
system disruption due to the Coronavirus-19 (COVID-19) 
pandemics, dedicated integrated service for people 
living with HIV (PLHIV) should be ensured to maintain 
retention to care and avoid loss to follow-up due to the 
fear of COVID-19  [4,  5]. Tailored ART, individualised 
follow-up and new technologies to support data-sharing 
between health-care professional caring for PLHIV and 
to deliver ART to patients are desperately needed [6, 7].
Again, from the Italian epidemiological picture, it is clear 
how aging of new infected patients should be a main 
concern, effectively addressing multi-morbidity, poly-
pharmacy, co-infections; thus, HIV-care is constantly 
becoming a sub-specialization of Infectious Diseases 
that needs continuous updating and that embraces 
other medical specializations (e.g. Internal Medicine, 
pharmacology, Geriatric, Public Health) [8].
Aim of this paper, in a view of “up-to-date patient-
centred medicine”, is to give nine ideas to improve HIV 
management in clinical practice during the COVID-19 
pandemic.
Methods
The text of this nine-point manuscript was ultimately 
organised in the following major paragraphs: i) HIV-
tailored follow-up; ii) integrated HIV outpatient service; 
iii) HIV online-consultation; iv) ART-delivering; v) ART-
monitoring; vi) inter-regional clinical data sharing; vii) 
pro-active screening; viii) HIV-dedicated wards; ix) HIV-
physician training; x) future challenges and conclusion.
Every paragraphs highlights how to implement the 
subject within the clinical practice.
HIV-tailored follow-up
Thanks to ART, sustained viral suppression (viral 
load < 50 copies/ml) and prompt immune stability (CD4+ 
cell count  >  500  cell/mm3) can be achieved, ensuring 
immunovirological benefits to our patients  [9,  10]. 
However, art became a life-long treatment that requires 
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laboratory monitoring, clinical follow-up visits, tailored 
regimens adjustments according to patient needs, side 
effects, drug-drug interactions (ddi), comorbidities, co-
infections, and availability of drugs, in order to preserve 
efficacy, safety and, ultimately, adherence to treatment 
and retention to care [11, 12].
Substantial time and costs for patients and healthcare 
systems are deployed to standard check-up, while 
individualised visits and laboratory monitoring should 
be tailored on patients’profile, enhancing patients’ 
quality of life and decreasing healthcare costs [9]. 
In the setting of acute infection, late presenter, and in any 
case in which patients need to start art, prompt antiviral 
treatment should be initiated.
For instance, in case of virological suppression, 
immunological recovery, good psychological and clinical 
condition, no comorbidities, no risk-factors for co-
infections, well tolerated art regimens, good adherence 
to treatment, and no complains by the patient, laboratory 
monitoring, co-infection screening, and clinical check-
up could be delayed every 6-8 months [13]. Vice-versa, 
if a patient displays risky behaviours for co-infections, 
immunovirological goals are not met, art regimen is 
leading to intolerance and/or ddis and/or scarce adherence 
to treatment, follow-up visits should be anticipated, even 
monthly, in order to offer counselling, timely screening, 
and treatment simplification to improve patients’ quality 
of life [14, 15].
Integrated HIV outpatient service
Hiv-outpatients service should be “patients-centered”, 
offering clinical answers to patient both for hiv related issues 
and non-hiv complications resulting from art, co-infections 
and/or aging, as well as prep and post-exposure prophylaxis 
(pep) [16, 17]. Scheduled follow-up visits with the possibility 
of specialists’consultation other than infectious diseases 
specialists (namely: pulmonologist, gastroenterologist, 
cardiologist, gynecologist, gerontologist, immunologist, 
psycologist, psychiatric, hospital pharmacist, cultural 
mediator as well as peer-patients meetings) can improve 
patients retention to care, creating an unique environment 
to pursue the goal of hiv-care. This integration can be done 
by a group of hospital in confined area.
HIV-online consultation
When disruption of normal health-care system procedures 
prevents access to care or when it is not feasible for the 
patient reaching her/his hiv-dedicated outpatient service, 
retention to care should be still ensured [18]. Telemedicine, 
with free online video-call and text-message reminders for 
appointment and art delivery, could overcome the problem 
created by interrupted hiv-services, avoiding exposure to 
pathogens in time of pandemics, offering continuum to 
care to our patients  [19]. However this consultation does 
not replace the face-to-face visit, but constitutes a new way 
of relating.
Art delivering
Again, if normal follow-up of PLWH is not possible or 
risky due to external conditions or patients’ inability, 
technology-supported ART delivery should be 
considered [20].
In sub-Saharan Africa, drone delivery of HIV test and ART 
has been found feasible as well as mobile fully-equipped 
ART clinics; this switching the paradigm from “patients 
go to ART” to “ART goes to patient”  [20]. Strategic 
placement of electronic pick-up machines, where registered 
patients can receive tailored treatment refill, coupled with 
text-message reminders on patients’ mobile phone, is 
another example of how ART delivering could be made 
more efficiently and safer for patients. Moreover, ART 
delivering shouldn’t be offered monthly, but according 
to patient’s peculiarity (adherence to treatment, effective 
presence at online tele-consultations), it can be delivered 
for the following 2-3 months, reducing costs.
Art monitoring
To fulfil the UNAIDS third “90” (viral suppression) 
ambitious goals, ART monitoring can be enhanced through 
periodic text reminder for ART administration, portable 
point-of-care HIV-viral load self-testing with results live-
delivered to health care providers, in order to timely decide 
possible clinical visit, further laboratory test (e.g. resistance 
testing, CD4+ cell count) and treatment changes [21, 22]. 
Indeed, treatment-as-prevention (TasP) can be achieved 
only if our patients are constantly virologically suppressed, 
highlighting how even the first two “90” of the UNAIDS 
strategy are linked to effective ART monitoring. ART 
monitoring includes for the HIV physician to be updated 
with new antiviral agents in commerce, possible side effects, 
DDIs, and with national and international guidelines, to 
promote best patients’care [23].
Inter-regional data sharing
To convey and uniform clinical data, clinical 
practices, monitoring patients’ laboratory exams and 
treatment’ history, discuss challenging cases among 
HIV physicians, and to share data to perform trial, an 
online inter-regional platform should be implemented 
between HIV-referral centres across the nation [24]. The 
experience of the “Rete Ligure”, in the Ligurian Region 
of Italy (extended to other infectious diseases such as 
tuberculosis), which enables physicians to track and 
monitor patients’ progress, retention to care, and HIV 
historical genotype as well as ART history, is an example 
of how health care providers can deliver a better service 
to patients and reduce ART related expenditure thanks to 
an interconnected health care system [25-27].
Pro-active screening
HIV screening, with opt-out strategy, should be 
part of daily clinical activity in Infectious Diseases 
wards, pregnant woman, outpatients service for 
sexually-transmitted infections, patients undergoing 
immunosuppressive treatment (e.g. oncology, haemato-
oncology), and before surgical procedures  [28]. 
Moreover, person at risk should be offered HIV 
periodically-scheduled screening in dedicated outpatient 
services or at home with self-testing with immediate 
linkage to care if resulted positive [28].
N. RICCARDI ET AL.
E32
However, “pro-active screening” does not involve just 
HIV-testing in at risk population, but regularly screening 
viral hepatitis (hepatitis A, hepatitis B, hepatitis C, 
hepatitis D), tuberculosis, human papilloma virus (HPV), 
opportunistic infections, sexually transmitted diseases, 
and, when actively circulating, virus-responsible for 
pandemic in PLHIV  [29,  30]. Active vaccination of 
vaccine-preventable infections should be promoted.
HIV-dedicated wards
Viruses with pandemic potential are emerging faster causing 
exponential growth of infected patients, reallocation of 
health-care resources, disruption of ambulatory services 
and fear of health-care settings  [18,  31]. However, 
preparedness to avoid to stop or to reduce HIV routine 
care should be prioritized, as well as the creation of HIV 
dedicated wards for patients that require hospitalization, 
with properly trained staff (doctors, pharmacists, nurses 
and other health care professions), screening for pandemic 
viruses prior-to-admission and linkage to HIV-outpatient 
service after discharge.
HIV-physician training
HIV care is evolving quickly and, to provide 
comprehensive primary health care services to PLHIV, it 
is necessary for young Infectious Diseases specialists to 
own a solid background in infectious diseases, internal 
medicine, and epidemiology. Moreover, HIV-specialists 
need to be updated on new drugs available, DDIs, 
comorbidities, PrEP, PEP, and psychological counselling 
at diagnosis and during follow-up  [32]. HIV-related 
continuing medical education should be encouraged and 
periodically done to awake and answer to intellectual 
challenges encountered by HIV physicians in daily 
practice (e.g. drug interactions between new ART 
regimens) and to care for the whole person rather than 
just to achieve viral suppression [33].
Future challenges and conclusion
Currently, online consultation, via email, in the Ligurian 
Region has been implemented, giving the chance to 
all patients to consult ID specialists even during lock-
down. In the next future, pro-active HIV screening 
should be encouraged among General Practice doctors, 
through dedicated courses by ID specialists, in order to 
implement the path to linkage to care. Moreover, annual 
inter-regional or national post-graduated course for 
ID specialist, willing to take care of PLWH, should be 
promoted. Finally, inter-regional data sharing through 
dedicated online platform should be implemented.
The over-mentioned goals may represent the first steps 
to improve HIV management in clinical practice to keep 
delivering to our patient the best possible care.
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